Compare ARK Genomic Revolution ETF (ARKG) vs J M Smucker Co (SJM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs J M Smucker Co — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while J M Smucker Co trades at $111.6 (market cap $11.93B). The key difference: J M Smucker Co pays a 3.94% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | SJM | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $117.05 |
52-Week Low | $23.09 | $89.53 |
Market Cap | — | $11.93B |
Enterprise Value | — | $18.96B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
SJM trades at $111.60, up 0.66% today, with technical indicators showing a bearish bias despite recent earnings beats. The company reported a net loss of $1.23 billion in 2025, though revenue grew to $8.73 billion. Analyst consensus is bullish with a $122.92 price target, but weak profitability metrics and high debt levels pose challenges. Recent news highlights mixed sentiment, with some outlets praising growth potential while others caution on sales pressure.
The outlook hinges on margin recovery in coffee and growth in Uncrustables, but fiscal 2027 sales guidance of a 3-4% decline tempers optimism. Risks include competitive pressures and debt management, while the 4% dividend yield offers income support. Upside depends on execution against muted growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
